These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 3001234)
1. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia. Powell BL; Capizzi RL; Lyerly ES; Cooper MR J Clin Oncol; 1986 Jan; 4(1):95-7. PubMed ID: 3001234 [TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission. Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354 [TBL] [Abstract][Full Text] [Related]
3. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638 [TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [TBL] [Abstract][Full Text] [Related]
5. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia]. Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050 [TBL] [Abstract][Full Text] [Related]
6. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Crowther D; Bateman CJ; Vartan CP; Whitehouse JM; Malpas JS; Fairley GH; Scott RB Br Med J; 1970 Nov; 4(5734):513-7. PubMed ID: 4921703 [TBL] [Abstract][Full Text] [Related]
9. Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. Nevill TJ; Benstead TJ; McCormick CW; Hayne OA Am J Hematol; 1989 Dec; 32(4):314-5. PubMed ID: 2554727 [TBL] [Abstract][Full Text] [Related]
10. [Low-dose ARA-C and HOAAP regimen in the treatment of adult acute nonlymphocytic leukemia: analysis of 59 cases]. Dong ZR; Yao EG; Xu SR Zhonghua Nei Ke Za Zhi; 1988 May; 27(5):300-2, 327. PubMed ID: 3197499 [No Abstract] [Full Text] [Related]
11. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446 [TBL] [Abstract][Full Text] [Related]
14. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205 [TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside in the consolidation therapy of acute nonlymphocytic leukemia in remission. Takaku F; Urabe A; Mizoguchi H; Hoshino S; Toyama K; Tanaka K; Nomura T; Dan K; Fujioka S; Saito T Semin Oncol; 1987 Jun; 14(2 Suppl 1):55-7. PubMed ID: 3589698 [No Abstract] [Full Text] [Related]
16. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City]. Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):139-42, 187. PubMed ID: 1395923 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of 17 cases of non-lymphoblastic acute leukemia with a combination of daunorubicin, cytosine and arabinoside]. Dini E; Barbui T; Cartei G; Chisesi T; Cazzavillan M; Battista R Minerva Med; 1975 Jul; 66(52):2619-2620. PubMed ID: 1057055 [No Abstract] [Full Text] [Related]
19. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cassileth PA; Katz ME Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749 [TBL] [Abstract][Full Text] [Related]
20. Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination. Amadori S; Petti MC; Mastrovincenzo C; Testa MG Acta Haematol; 1979; 61(5):237-42. PubMed ID: 111451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]